{"commentary":{"count":5,"free_build_floor":8,"listing_floor":3,"by_channel":{"podcast":3,"youtube":2},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":false},"name":"MONARCH 1","nct_id":"NCT02102490","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=monarch-1-nct02102490. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources"},"registry":{"acronym":"MONARCH 1","arms":[{"description":"200 milligrams (mg) abemaciclib given orally once every 12 hours for 28 days (1 cycle). Participants may continue to receive treatment until discontinuation criteria are met.","label":"Abemaciclib","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2018-10-22","type":"ACTUAL"},"conditions":["Metastatic Breast Cancer"],"enrollment":{"count":132,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Abemaciclib","type":"DRUG"}],"last_update":"2020-01-21","lead_sponsor":"Eli Lilly and Company","official_title":"A Phase 2 Study of LY2835219 for Patients With Previously Treated Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2016-04-30","type":"ACTUAL"},"primary_outcomes":[{"measure":"Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response Rate [ORR])","timeFrame":"From Date of First Dose until Disease Progression or Death Due to Any Cause (Up To 14 Months)"}],"references":[{"citation":"Dickler MN, Tolaney SM, Rugo HS, Cortes J, Dieras V, Patt D, Wildiers H, Hudis CA, O'Shaughnessy J, Zamora E, Yardley DA, Frenzel M, Koustenis A, Baselga J. MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2- Metastatic Breast Cancer. Clin Cancer Res. 2017 Sep 1;23(17):5218-5224. doi: 10.1158/1078-0432.CCR-17-0754. Epub 2017 May 22.","pmid":"28533223","type":"RESULT"}],"start_date":{"date":"2014-06-10","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Abemaciclib (LY2835219) In Participants With Previously Treated Breast Cancer That Has Spread","url":"https://clinicaltrials.gov/study/NCT02102490"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/monarch-1-nct02102490"}